Hiroki Hamamoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroki Hamamoto has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Keitaro Tanaka
Department of General and Gastroenterological Surgery Osaka Medical and Pharmaceutical University Takatsuki‐shi Osaka Japan
22 shared publicationsKazuhisa Uchiyama
Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
20 shared publicationsMasatsugu Ishii
Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
16 shared publicationsShinsuke Masubuchi
Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
15 shared publicationsWataru Osumi
Department of General and Gastroenterological Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan
15 shared publicationsJunji Okuda
Department of General and Gastroenterological Surgery Osaka Medical and Pharmaceutical University Takatsuki Japan
14 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Wiley in Annals of Gastroenterological Surgery
Short‐Term Outcomes of Transanal Total Mesorectal Excision for Rectal Cancer: A Multicenter Propensity Score‐Matched Analysis Comparing Patients With and Without Preoperative Neoadjuvant Therapy
Aim: To evaluate the association between preoperative neoadjuvant therapy and short‐term outcomes of transanal total mesorectal excision for rectal cancer. Methods: We retrospectively analyzed patients who underwent transanal total mesorectal excision at 26 Japanese institutions between 2012 and 2019. Patients who received neoadjuvant therapy were matched 1:1 with patients who did not. Perioperative, postoperative, and pathological outcomes were compared. Results: After matching, 294 patients (147 per group) were analyzed. Operative time was longer in the neoadjuvant therapy group than in the non‐neoadjuvant therapy group (median, 510.0 vs. 382.0 min), with an adjusted mean difference of 129.25 min (95% CI, 87.90–170.59; p < 0.001). Clavien–Dindo grade ≥ III complications occurred in 18/147 patients (12.2%) without neoadjuvant therapy and 16/147 (10.9%) with neoadjuvant therapy (adjusted OR, 0.90; 95% CI, 0.44–1.85; p = 0.769). Full‐cohort conventional and Firth logistic analyses and marginal standardization likewise did not identify a statistically significant association. Neoadjuvant therapy remained associated with longer operative time after adjustment for operative procedure, lateral pelvic lymph node dissection, and abdominal approach. Resection‐margin involvement did not differ significantly between groups. Conclusion: Neoadjuvant therapy was associated with longer operative time during transanal total mesorectal excision, whereas no statistically significant association with severe postoperative morbidity was detected. Sensitivity analyses likewise did not identify a statistically significant association, supporting the technical feasibility of transanal total mesorectal excision after neoadjuvant therapy in experienced centers.
- 14 October 2026
- Published by Wiley in Annals of Gastroenterological Surgery
Open AccessShort‐Term Outcomes of Transanal Total Mesorectal Excision for Rectal Cancer: A Multicenter Propensity Score‐Matched Analysis Comparing Patients With and Without Preoperative Neoadjuvant Therapy
Aim: To evaluate the association between preoperative neoadjuvant therapy and short‐term outcomes of transanal total mesorectal excision for rectal cancer. Methods: We retrospectively analyzed patients who underwent transanal total mesorectal excision at 26 Japanese institutions between 2012 and 2019. Patients who received neoadjuvant therapy were matched 1:1 with patients who did not. Perioperative, postoperative, and pathological outcomes were compared. Results: After matching, 294 patients (147 per group) were analyzed. Operative time was longer in the neoadjuvant therapy group than in the non‐neoadjuvant therapy group (median, 510.0 vs. 382.0 min), with an adjusted mean difference of 129.25 min (95% CI, 87.90–170.59; p < 0.001). Clavien–Dindo grade ≥ III complications occurred in 18/147 patients (12.2%) without neoadjuvant therapy and 16/147 (10.9%) with neoadjuvant therapy (adjusted OR, 0.90; 95% CI, 0.44–1.85; p = 0.769). Full‐cohort conventional and Firth logistic analyses and marginal standardization likewise did not identify a statistically significant association. Neoadjuvant therapy remained associated with longer operative time after adjustment for operative procedure, lateral pelvic lymph node dissection, and abdominal approach. Resection‐margin involvement did not differ significantly between groups. Conclusion: Neoadjuvant therapy was associated with longer operative time during transanal total mesorectal excision, whereas no statistically significant association with severe postoperative morbidity was detected. Sensitivity analyses likewise did not identify a statistically significant association, supporting the technical feasibility of transanal total mesorectal excision after neoadjuvant therapy in experienced centers.
- Open Access
- 5 June 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (5) , 1594-1601
Translational Gap in Biomarker Discovery: Tumor Surface Markers Rarely Mirror Circulating Levels
Background: Tumor‐associated cell surface proteins are frequently proposed as circulating biomarkers for colorectal cancer (CRC) based on their high tumor expression. However, many candidates identified through tissue‐based analyses fail to translate into clinically useful biomarkers. We investigated the translational gap between tissue‐level expression and circulating detectability in CRC, focusing on molecular subtypes defined by caudal‐type homeobox 2 (CDX2) expression. Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA) were analyzed to identify cell surface markers differentially expressed between CDX2‐Low and CDX2‐High CRCs. A clinical cohort of right‐sided CRC patients was evaluated using paired tumor tissue and preoperative plasma samples. CDX2 expression was assessed by immunohistochemistry, and circulating concentrations of selected cell surface proteins were quantified using a multiplex ELISA platform. Results: Several tumor‐associated cell surface markers exhibited marked CDX2‐dependent differences in tissue expression. However, for most markers, circulating plasma levels did not mirror tissue‐level patterns. CEACAM1 was the sole marker demonstrating concordant CDX2‐dependent differences in both tumor tissue and plasma, with significantly lower levels in CDX2‐Low CRCs. In contrast, CEACAM5 showed a dissociation between tissue expression and circulating levels, despite analytical validation against serum carcinoembryonic antigen (CEA). Conclusions: Our findings demonstrate that tumor overexpression of cell surface markers does not necessarily translate into detectable circulating biomarkers. This translational disconnect underscores limitations of biomarker selection strategies based solely on tissue expression and highlights the importance of integrating systemic biology into biomarker development. While some tumor‐associated proteins may lack utility as circulating biomarkers, they may still represent viable therapeutic targets in CRC.
- 5 June 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (5) , 1594-1601
Open AccessTranslational Gap in Biomarker Discovery: Tumor Surface Markers Rarely Mirror Circulating Levels
Background: Tumor‐associated cell surface proteins are frequently proposed as circulating biomarkers for colorectal cancer (CRC) based on their high tumor expression. However, many candidates identified through tissue‐based analyses fail to translate into clinically useful biomarkers. We investigated the translational gap between tissue‐level expression and circulating detectability in CRC, focusing on molecular subtypes defined by caudal‐type homeobox 2 (CDX2) expression. Methods: Transcriptomic data from The Cancer Genome Atlas (TCGA) were analyzed to identify cell surface markers differentially expressed between CDX2‐Low and CDX2‐High CRCs. A clinical cohort of right‐sided CRC patients was evaluated using paired tumor tissue and preoperative plasma samples. CDX2 expression was assessed by immunohistochemistry, and circulating concentrations of selected cell surface proteins were quantified using a multiplex ELISA platform. Results: Several tumor‐associated cell surface markers exhibited marked CDX2‐dependent differences in tissue expression. However, for most markers, circulating plasma levels did not mirror tissue‐level patterns. CEACAM1 was the sole marker demonstrating concordant CDX2‐dependent differences in both tumor tissue and plasma, with significantly lower levels in CDX2‐Low CRCs. In contrast, CEACAM5 showed a dissociation between tissue expression and circulating levels, despite analytical validation against serum carcinoembryonic antigen (CEA). Conclusions: Our findings demonstrate that tumor overexpression of cell surface markers does not necessarily translate into detectable circulating biomarkers. This translational disconnect underscores limitations of biomarker selection strategies based solely on tissue expression and highlights the importance of integrating systemic biology into biomarker development. While some tumor‐associated proteins may lack utility as circulating biomarkers, they may still represent viable therapeutic targets in CRC.
- Open Access
- 13 March 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Falciform ligament interposition technique: an optimized drainage strategy after pancreaticoduodenectomy
Postoperative pancreatic fistula (POPF) is a major complication following pancreaticoduodenectomy (PD) and is often associated with delayed recovery and po
- 13 March 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Open AccessFalciform ligament interposition technique: an optimized drainage strategy after pancreaticoduodenectomy
Postoperative pancreatic fistula (POPF) is a major complication following pancreaticoduodenectomy (PD) and is often associated with delayed recovery and po
- Open Access
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0715
Rapid Development of Diffuse-Type Remnant Pancreatic Cancer Following Obstructive Pancreatitis after Pancreaticoduodenectomy for Distal Bile Duct Carcinoma: A Case Report
INTRODUCTION: Distal bile duct carcinoma (DBDC) and pancreatic ductal adenocarcinoma (PDAC) are aggressive malignancies; however, their metachronous occurrence within a short postoperative timeframe is extremely rare. We present an extremely rare case of diffuse-type PDAC that rapidly developed only 16 months after curative resection of DBDC.CASE PRESENTATION: A 60-year-old woman presented with obstructive jaundice. Contrast-enhanced CT revealed circumferential wall thickening with enhancement in the intrapancreatic bile duct. Endoscopic ultrasound-guided tissue acquisition confirmed adenocarcinoma, resulting in a diagnosis of resectable DBDC. She underwent laparoscopy-assisted subtotal stomach-preserving pancreaticoduodenectomy, and the pathology demonstrated Stage IIB (pT2N1M0; UICC/AJCC 8th edition). The resection margin was negative (R0). Adjuvant chemotherapy with gemcitabine, cisplatin, and S-1 was administered for 3 months. Follow-up imaging at 16 months postoperatively revealed newly-developed and progressive main pancreatic duct (MPD) dilatation, diffuse enlargement of the remnant pancreas, and a poorly enhancing mass in the pancreatic tail. The patient also experienced epigastric and back pain, raising suspicion of obstructive pancreatitis. Endoscopic ultrasound-guided sampling again demonstrated adenocarcinoma, leading to a clinical diagnosis of de novo remnant pancreatic cancer. Total remnant pancreatectomy was therefore performed. Histopathological examination revealed moderately to poorly differentiated adenocarcinoma with widespread infiltration of the entire pancreas, classified as Stage III (ypT3N2M0; UICC/AJCC 8th edition). Comprehensive genomic profiling identified canonical PDAC driver alterations. These included KRAS, TP53, CDKN2A, and SMAD4, providing molecular confirmation of a de novo pancreatic origin. The patient died 6 months after the second surgery due to aggressive disease progression.CONCLUSIONS: This case highlights a rare, rapidly occurring metachronous combination of DBDC and highly aggressive diffuse-type pancreatic cancer. To our knowledge, this is the first case report of surgically treated remnant pancreatic cancer after DBDC with comprehensive genetic profiling. Obstructive pancreatitis secondary to pancreaticojejunostomy stricture was the most plausible underlying carcinogenic factor. Vigilant surveillance of postoperative morphological changes, particularly progressive MPD dilatation, is required to prevent delayed recognition of fatal outcomes.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1) , cr.25-0715
Open AccessRapid Development of Diffuse-Type Remnant Pancreatic Cancer Following Obstructive Pancreatitis after Pancreaticoduodenectomy for Distal Bile Duct Carcinoma: A Case Report
INTRODUCTION: Distal bile duct carcinoma (DBDC) and pancreatic ductal adenocarcinoma (PDAC) are aggressive malignancies; however, their metachronous occurrence within a short postoperative timeframe is extremely rare. We present an extremely rare case of diffuse-type PDAC that rapidly developed only 16 months after curative resection of DBDC.CASE PRESENTATION: A 60-year-old woman presented with obstructive jaundice. Contrast-enhanced CT revealed circumferential wall thickening with enhancement in the intrapancreatic bile duct. Endoscopic ultrasound-guided tissue acquisition confirmed adenocarcinoma, resulting in a diagnosis of resectable DBDC. She underwent laparoscopy-assisted subtotal stomach-preserving pancreaticoduodenectomy, and the pathology demonstrated Stage IIB (pT2N1M0; UICC/AJCC 8th edition). The resection margin was negative (R0). Adjuvant chemotherapy with gemcitabine, cisplatin, and S-1 was administered for 3 months. Follow-up imaging at 16 months postoperatively revealed newly-developed and progressive main pancreatic duct (MPD) dilatation, diffuse enlargement of the remnant pancreas, and a poorly enhancing mass in the pancreatic tail. The patient also experienced epigastric and back pain, raising suspicion of obstructive pancreatitis. Endoscopic ultrasound-guided sampling again demonstrated adenocarcinoma, leading to a clinical diagnosis of de novo remnant pancreatic cancer. Total remnant pancreatectomy was therefore performed. Histopathological examination revealed moderately to poorly differentiated adenocarcinoma with widespread infiltration of the entire pancreas, classified as Stage III (ypT3N2M0; UICC/AJCC 8th edition). Comprehensive genomic profiling identified canonical PDAC driver alterations. These included KRAS, TP53, CDKN2A, and SMAD4, providing molecular confirmation of a de novo pancreatic origin. The patient died 6 months after the second surgery due to aggressive disease progression.CONCLUSIONS: This case highlights a rare, rapidly occurring metachronous combination of DBDC and highly aggressive diffuse-type pancreatic cancer. To our knowledge, this is the first case report of surgically treated remnant pancreatic cancer after DBDC with comprehensive genetic profiling. Obstructive pancreatitis secondary to pancreaticojejunostomy stricture was the most plausible underlying carcinogenic factor. Vigilant surveillance of postoperative morphological changes, particularly progressive MPD dilatation, is required to prevent delayed recognition of fatal outcomes.
- Open Access
- 6 October 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (10) , e70255
Quality of life after laparoscopic surgery for very low rectal cancer: A sub‐analysis of the ultimate trial
Aim: Laparoscopic low anterior resection is widely used for treating rectal cancer; however, postoperative complications frequently result in a marked deterioration in the patients' quality of life (QOL). This study aimed to investigate the trajectory of QOL recovery and identify the risk factors affecting QOL in patients undergoing laparoscopic surgery for very low rectal cancer. Method: This prospective, multi‐institutional, single‐arm, phase‐II trial examined the outcomes of laparoscopic surgery in patients with very low rectal cancer (p = 0.0084) and Wexner score ≥9 at 1 year after surgery as a predictor of lower RCS score ( p = 0.0116). Conclusion: QOL after laparoscopic surgery for low‐lying rectal cancer is generally acceptable. Patients with stage III cancer experience prolonged physical challenges, whereas those with bowel dysfunction struggle with role/social domains of QOL. Targeted interventions should be implemented to address these issues.
- 6 October 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (10) , e70255
Open AccessQuality of life after laparoscopic surgery for very low rectal cancer: A sub‐analysis of the ultimate trial
Aim: Laparoscopic low anterior resection is widely used for treating rectal cancer; however, postoperative complications frequently result in a marked deterioration in the patients' quality of life (QOL). This study aimed to investigate the trajectory of QOL recovery and identify the risk factors affecting QOL in patients undergoing laparoscopic surgery for very low rectal cancer. Method: This prospective, multi‐institutional, single‐arm, phase‐II trial examined the outcomes of laparoscopic surgery in patients with very low rectal cancer (p = 0.0084) and Wexner score ≥9 at 1 year after surgery as a predictor of lower RCS score ( p = 0.0116). Conclusion: QOL after laparoscopic surgery for low‐lying rectal cancer is generally acceptable. Patients with stage III cancer experience prolonged physical challenges, whereas those with bowel dysfunction struggle with role/social domains of QOL. Targeted interventions should be implemented to address these issues.
- Open Access
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43758
Robot-assisted surgery for rectal cancer with tumor-associated dermatomyositis during preoperative chemotherapy: A case report and literature review
Rationale: Dermatomyositis (DM) is a systemic inflammatory disorder involving the muscles and skin and is often associated with malignancies in adults. Anti-transcriptional intermediary factor 1-gamma (anti-TIF1-γ) antibodies are specific markers of a subset of DM with a high risk of cancer, highlighting the importance of recognizing this paraneoplastic syndrome for early diagnosis and treatment. This report describes a rare case of tumor-associated DM that developed during chemotherapy for advanced rectal cancer and emphasizes the importance of multidisciplinary management in such conditions. Patient concerns: A 75-year-old woman presented with rectal bleeding and progressive symptoms, including severe erythema, rash, muscle weakness, and general fatigue, following preoperative chemotherapy for rectal cancer. The symptoms severely impacted her quality of life, raising concerns about a potential paraneoplastic syndrome. Diagnoses: The patient was diagnosed with tumor-associated DM based on clinical findings of a heliotrope rash, Gottron’s sign, and elevated muscle enzyme levels. The presence of anti-TIF1-γ antibodies confirmed the diagnosis. Preoperative evaluation identified rectal cancer as stage IIa (pT3, N0, M0) and the likely underlying malignancy contributing to DM. Interventions: The patient underwent immunotherapy with steroids and high-dose intravenous immunoglobulin, which stabilized her condition. Subsequently, a robot-assisted Hartmann’s operation was performed to resect the rectal tumor and establish a colostomy. Postoperative care included monitoring for DM symptom resolution and managing her nutritional and rehabilitation needs. Outcomes: Within 3 weeks of surgery, the patient’s muscle enzyme levels normalized, and her symptoms, including erythema and muscle weakness, resolved. Follow-up evaluations showed no recurrence of DM or cancer over the subsequent year, indicating a successful outcome with a multidisciplinary approach. Lessons: This case underscores the importance of early recognition and management of paraneoplastic syndromes such as tumor-associated DM. A multidisciplinary approach combining immunotherapy and surgical intervention for the underlying malignancy can lead to favorable outcomes. This case also highlights the significance of long-term monitoring for both cancer recurrence and autoimmune complications in such patients.
- 8 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (32) , e43758
Open AccessRobot-assisted surgery for rectal cancer with tumor-associated dermatomyositis during preoperative chemotherapy: A case report and literature review
Rationale: Dermatomyositis (DM) is a systemic inflammatory disorder involving the muscles and skin and is often associated with malignancies in adults. Anti-transcriptional intermediary factor 1-gamma (anti-TIF1-γ) antibodies are specific markers of a subset of DM with a high risk of cancer, highlighting the importance of recognizing this paraneoplastic syndrome for early diagnosis and treatment. This report describes a rare case of tumor-associated DM that developed during chemotherapy for advanced rectal cancer and emphasizes the importance of multidisciplinary management in such conditions. Patient concerns: A 75-year-old woman presented with rectal bleeding and progressive symptoms, including severe erythema, rash, muscle weakness, and general fatigue, following preoperative chemotherapy for rectal cancer. The symptoms severely impacted her quality of life, raising concerns about a potential paraneoplastic syndrome. Diagnoses: The patient was diagnosed with tumor-associated DM based on clinical findings of a heliotrope rash, Gottron’s sign, and elevated muscle enzyme levels. The presence of anti-TIF1-γ antibodies confirmed the diagnosis. Preoperative evaluation identified rectal cancer as stage IIa (pT3, N0, M0) and the likely underlying malignancy contributing to DM. Interventions: The patient underwent immunotherapy with steroids and high-dose intravenous immunoglobulin, which stabilized her condition. Subsequently, a robot-assisted Hartmann’s operation was performed to resect the rectal tumor and establish a colostomy. Postoperative care included monitoring for DM symptom resolution and managing her nutritional and rehabilitation needs. Outcomes: Within 3 weeks of surgery, the patient’s muscle enzyme levels normalized, and her symptoms, including erythema and muscle weakness, resolved. Follow-up evaluations showed no recurrence of DM or cancer over the subsequent year, indicating a successful outcome with a multidisciplinary approach. Lessons: This case underscores the importance of early recognition and management of paraneoplastic syndromes such as tumor-associated DM. A multidisciplinary approach combining immunotherapy and surgical intervention for the underlying malignancy can lead to favorable outcomes. This case also highlights the significance of long-term monitoring for both cancer recurrence and autoimmune complications in such patients.
- Open Access
- 9 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (6) , 1215-1224
Patient‐Reported Outcomes and Surgical Results of Hand‐Sewn Versus Stapled Anastomosis for Lower Rectal Cancer Located 4–5 cm From the Anal Verge: A Subanalysis of the Ultimate Study
Background: Preserving anorectal function while achieving oncological success is crucial in the treatment of lower rectal cancer near the anal canal. Despite advancements in laparoscopic surgery that facilitate anal preservation, post‐operative anorectal dysfunction considerably affects quality of life. Both hand‐sewn and stapled anastomoses are suitable options for tumors located 4–5 cm from the anus. However, evidence comparing the functional outcomes and complications associated with both anastomosis methods is lacking. Methods: This multicenter, single‐arm prospective study included patients with cT1‐T2/N0/M0 adenocarcinoma located 4–5 cm from the anal verge, scheduled for upfront laparoscopic surgery. Anorectal function, post‐operative complications, urinary and male sexual function, and oncological outcomes were assessed using the validated scores. Results: A total of 135 patients were analyzed and divided into hand‐sewn ( n = 65) and stapled ( n = 70) groups. The patient characteristics were similar, except for the tumors in the hand‐sewn group located 1 mm closer to the anal verge. No significant differences were observed in the post‐operative complications. Anorectal function, measured using Wexner scores, worsened at 3 months postoperatively and gradually improved in both groups. At 3, 6, 12, 24, and 36 months, the stapled group consistently showed better Wexner scores than the hand‐sewn group. Urinary function, sexual function, and oncological outcomes were similar in both groups. Conclusion: Stapled anastomosis may provide better anorectal function with comparable safety and oncological outcomes to hand‐sewn anastomosis. Therefore, stapled anastomosis may be preferred for tumors located 4–5 cm from the anal verge to ensure oncological safety. Trial Registration: This study was registered in the UMIN Clinical Trials Registry System (UMIN 000011750)
- 9 July 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 9 (6) , 1215-1224
Open AccessPatient‐Reported Outcomes and Surgical Results of Hand‐Sewn Versus Stapled Anastomosis for Lower Rectal Cancer Located 4–5 cm From the Anal Verge: A Subanalysis of the Ultimate Study
Background: Preserving anorectal function while achieving oncological success is crucial in the treatment of lower rectal cancer near the anal canal. Despite advancements in laparoscopic surgery that facilitate anal preservation, post‐operative anorectal dysfunction considerably affects quality of life. Both hand‐sewn and stapled anastomoses are suitable options for tumors located 4–5 cm from the anus. However, evidence comparing the functional outcomes and complications associated with both anastomosis methods is lacking. Methods: This multicenter, single‐arm prospective study included patients with cT1‐T2/N0/M0 adenocarcinoma located 4–5 cm from the anal verge, scheduled for upfront laparoscopic surgery. Anorectal function, post‐operative complications, urinary and male sexual function, and oncological outcomes were assessed using the validated scores. Results: A total of 135 patients were analyzed and divided into hand‐sewn ( n = 65) and stapled ( n = 70) groups. The patient characteristics were similar, except for the tumors in the hand‐sewn group located 1 mm closer to the anal verge. No significant differences were observed in the post‐operative complications. Anorectal function, measured using Wexner scores, worsened at 3 months postoperatively and gradually improved in both groups. At 3, 6, 12, 24, and 36 months, the stapled group consistently showed better Wexner scores than the hand‐sewn group. Urinary function, sexual function, and oncological outcomes were similar in both groups. Conclusion: Stapled anastomosis may provide better anorectal function with comparable safety and oncological outcomes to hand‐sewn anastomosis. Therefore, stapled anastomosis may be preferred for tumors located 4–5 cm from the anal verge to ensure oncological safety. Trial Registration: This study was registered in the UMIN Clinical Trials Registry System (UMIN 000011750)
- Open Access
- 25 May 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (5) , e70129
A multicentre prospective study of anal function after laparoscopic ultra‐low rectal cancer surgery using a mixed‐effects model
Aim: Abdominoperineal resection with permanent colostomy has historically been performed for very low rectal cancer located near the anal canal. Anus‐preserving surgeries, such as intersphincteric resection (ISR) and low anterior resection (LAR), have recently become more common. However, postoperative anal function is a concern in these surgeries when the anastomosis is very low. The aim of this study was to examine changes in anal function and factors that worsen anal function after surgery for rectal cancer.Method: A multicentre (47 facilities), non‐randomized, single‐arm phase II trial was conducted prospectively using the Wexner score questionnaire between 2014 and 2017. A total of 278 patients who underwent laparoscopic surgery for clinical Stage I very low rectal cancer were analysed using a mixed‐effects model.Results: Anal function temporarily worsened 3 months after surgery, but gradually recovered and spontaneously returned to an acceptable level in 3 years. In a comparison of surgical procedures, anal function was significantly better after LAR than after any type of ISR. There was little difference in anal function after total ISR, subtotal ISR and partial ISR. In the mixed‐effects model analysis, ISR and older age (≥75 years) were identified as independent factors that worsened postoperative anal function.Conclusions: The results showed early deterioration of anal function followed by gradual improvement to an acceptable level after surgery. There is a higher risk of poor postoperative anal function after ISR and in older patients, and these risk factors should be communicated to patients when obtaining consent for the surgery.
- 25 May 2025
- Published by Wiley in Colorectal Disease
- Vol. 27 (5) , e70129
Open AccessA multicentre prospective study of anal function after laparoscopic ultra‐low rectal cancer surgery using a mixed‐effects model
Aim: Abdominoperineal resection with permanent colostomy has historically been performed for very low rectal cancer located near the anal canal. Anus‐preserving surgeries, such as intersphincteric resection (ISR) and low anterior resection (LAR), have recently become more common. However, postoperative anal function is a concern in these surgeries when the anastomosis is very low. The aim of this study was to examine changes in anal function and factors that worsen anal function after surgery for rectal cancer.Method: A multicentre (47 facilities), non‐randomized, single‐arm phase II trial was conducted prospectively using the Wexner score questionnaire between 2014 and 2017. A total of 278 patients who underwent laparoscopic surgery for clinical Stage I very low rectal cancer were analysed using a mixed‐effects model.Results: Anal function temporarily worsened 3 months after surgery, but gradually recovered and spontaneously returned to an acceptable level in 3 years. In a comparison of surgical procedures, anal function was significantly better after LAR than after any type of ISR. There was little difference in anal function after total ISR, subtotal ISR and partial ISR. In the mixed‐effects model analysis, ISR and older age (≥75 years) were identified as independent factors that worsened postoperative anal function.Conclusions: The results showed early deterioration of anal function followed by gradual improvement to an acceptable level after surgery. There is a higher risk of poor postoperative anal function after ISR and in older patients, and these risk factors should be communicated to patients when obtaining consent for the surgery.